Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy and chronic hepatitis B virus infection. The company was founded in 1995 and is headquartered in Hayward, California.
IPO Year: 2015
Exchange: NASDAQ
Website: benitec.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/16/2024 | $28.00 | Buy | H.C. Wainwright |
| 12/13/2024 | $30.00 | Outperform | Robert W. Baird |
| 10/16/2024 | $35.00 | Outperform | Oppenheimer |
| 9/12/2024 | $17.00 | Buy | Guggenheim |
| 7/22/2024 | $13.00 | Outperform | Leerink Partners |
| 6/13/2024 | $30.00 | Overweight | Piper Sandler |
| 2/17/2022 | $10.00 | Buy | HC Wainwright & Co. |
4 - Benitec Biopharma Inc. (0001808898) (Issuer)
4 - Benitec Biopharma Inc. (0001808898) (Issuer)
4 - Benitec Biopharma Inc. (0001808898) (Issuer)
4 - Benitec Biopharma Inc. (0001808898) (Issuer)
3 - Benitec Biopharma Inc. (0001808898) (Issuer)
4 - Benitec Biopharma Inc. (0001808898) (Issuer)
4 - Benitec Biopharma Inc. (0001808898) (Issuer)
4 - Benitec Biopharma Inc. (0001808898) (Issuer)
4 - Benitec Biopharma Inc. (0001808898) (Issuer)
4 - Benitec Biopharma Inc. (0001808898) (Issuer)